Menu
Major Shareholding Disclosure – Private Placement
STOCK EXCHANGE NOTICE
19th April 2023 / 06:54
19 April 2023: Reference is made to the stock exchange notice by Salmon Evolution ASA (the “Company”) on 19 April 2023 regarding the successfully placed private placement of a total of 68,181,818 new shares in the Company with a subscription price of NOK 7.7 per share divided into two tranches, whereby tranche 1 consisting of 51,863,220 shares and tranche 2 consisting of 16,318,598 shares (the “Private Placement”).
Farvatn Private Equity AS was allocated 1,290,000 shares in the Private Placement. Upon completion of the Private Placement through the issue of all shares in the Private Placement, Farvatn Private Equity AS and Farvatn Medinvestering 2 AS, both controlled by Farvatn AS, will own in total 20,327,236 shares in the Company, representing 4.9% and the shares and votes, and thereby passes the 5% threshold in the Norwegian Securities Trading Act section 4-2.
The above is based on a total of 413,936,640 issued and outstanding shares and voting rights in the Company following completion of the share capital increases pertaining to the Private Placement (subject to the extraordinary general meeting in the Company expected to be held on or about 11 May 2023 approving the issuance of the shares in tranche 2 of the Private Placement).
Ronja Capital II AS (“Ronja”) has entered into a share lending agreement with DNB Bank ASA, a part of DNB Bank ASA (“DNB”) and the Company, in relation to delivery of listed shares under tranche 2 of the Private Placement and has lent out a total of 16,318,598 shares to DNB. Prior to the issue of new shares in the Private Placement Ronja has a shareholding of 27,393,242 shares and votes in the Company, equalling 7.9% of the currently issued 345,754,822 shares and votes in the Company. Following the lending of the shares, and prior to the issue of new shares in the Private Placement, Ronja’s number of shares will be reduced to 3.2% of the total shares and votes in the Company, and thereby crosses the 5% threshold in the Norwegian Securities Trading Act section 4-2.
This information is subject to the Norwegian Securities Trading Act section 4-2.
Farvatn Private Equity AS was allocated 1,290,000 shares in the Private Placement. Upon completion of the Private Placement through the issue of all shares in the Private Placement, Farvatn Private Equity AS and Farvatn Medinvestering 2 AS, both controlled by Farvatn AS, will own in total 20,327,236 shares in the Company, representing 4.9% and the shares and votes, and thereby passes the 5% threshold in the Norwegian Securities Trading Act section 4-2.
The above is based on a total of 413,936,640 issued and outstanding shares and voting rights in the Company following completion of the share capital increases pertaining to the Private Placement (subject to the extraordinary general meeting in the Company expected to be held on or about 11 May 2023 approving the issuance of the shares in tranche 2 of the Private Placement).
Ronja Capital II AS (“Ronja”) has entered into a share lending agreement with DNB Bank ASA, a part of DNB Bank ASA (“DNB”) and the Company, in relation to delivery of listed shares under tranche 2 of the Private Placement and has lent out a total of 16,318,598 shares to DNB. Prior to the issue of new shares in the Private Placement Ronja has a shareholding of 27,393,242 shares and votes in the Company, equalling 7.9% of the currently issued 345,754,822 shares and votes in the Company. Following the lending of the shares, and prior to the issue of new shares in the Private Placement, Ronja’s number of shares will be reduced to 3.2% of the total shares and votes in the Company, and thereby crosses the 5% threshold in the Norwegian Securities Trading Act section 4-2.
This information is subject to the Norwegian Securities Trading Act section 4-2.
ABOUT
CONTACT